

I. AMENDMENTS

In the claims:

sub C² ^{amended}
1. A method for treating intracellular infections with warm-blooded animals,
comprising:

- B¹
- (a) administering to a warm-blooded animal a gene delivery vehicle comprising a polynucleotide encoding at least one immunogenic portion of an antigen derived from an intracellular pathogen; and
 - (b) administering to said warm-blooded animal a protein which comprises said immunogenic portion of said antigen, such that an immune response is generated.

B²

3. (Amended) The method according to claim 1, wherein said protein is administered prior to administration of said gene delivery vehicle.

sub C³
B³

5. (Amended) The method according to claim 3, wherein said viral antigen is obtained from a virus selected from the group consisting of hepatitis, feline immunodeficiency virus (FIV), and human immunodeficiency virus (HIV).

B⁴

11. (Amended) The method according to claim 1, wherein said gene delivery vehicle is a recombinant retrovirus.

12. (Amended) The method according to claim 1, wherein said gene delivery vehicle is selected from the group consisting of alphaviruses, adeno-associated virus and parvovirus.

13. (Amended) The method according to claim 1, wherein said gene delivery

vehicle is a nucleic acid expression vector, or a eukaryotic layered vector initiation system.

B⁴

14. (Amended) A composition comprising a gene delivery vehicle comprising a polynucleotide encoding at least one immunogenic portion of an antigen derived from an intracellular pathogen, a protein which comprises said immunogenic portion of said antigen, and a pharmaceutically acceptable carrier or diluent.

B⁵

17. (Amended) The composition according to claim 16, wherein said viral antigen is obtained from a virus selected from the group consisting of hepatitis, feline immunodeficiency virus (FIV), and human immunodeficiency virus (HIV).

B⁶

21. (Amended) The composition according to claim 20, wherein said hepatitis C antigen is selected from the group consisting of core antigen C, E1, E2/NS1, NS2, NS3, NS4 and NS5.

B⁷

23. (Amended) The composition according to claim 1, wherein said gene delivery vehicle is a recombinant retrovirus.

24. (New) The method of claim 1, wherein the gene delivery vehicle comprises naked DNA.

B⁸

sub c⁴ → 25. (New) The composition of claim 1, wherein the gene delivery vehicle comprises naked DNA.